How many institutions held CHRS - Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share in Q2 2017?

105 institutional investors reported CHRS - Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share for Q2 2017. Use the holders table for investor-level position and value details.

Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS)

Q: What does CUSIP 19249H103 represent in this 13F holders report?

CUSIP 19249H103 is the security identifier for CHRS - Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

CUSIP: 19249H103

Q2 2017 13F Holders as of 30 Jun 2017

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 154,721,181
Total 13F shares: 40,123,971
Share change: +3,042,713
Total reported value: $575,784,532
Put/Call ratio: 39%
Price per share: $14.35
Number of holders: 105
Value change: +$26,148,562
Number of buys: 72
Number of sells: 43

Quarterly Holders Quick Answers

What is CUSIP 19249H103?
CUSIP 19249H103 identifies CHRS - Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2017
Previous quarter: Q1 2017

Recent filing periods for CUSIP 19249H103:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CHRS - Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F	Company	5%	7,671,981	$162,262,000	—	31 Mar 2017	13F
Kohlberg Kravis Roberts & Co. L.P.	13F	Company	2%	3,055,055	$64,614,000	—	31 Mar 2017	13F
BlackRock Finance, Inc.	13F	Company	1.8%	2,844,827	$60,168,000	—	31 Mar 2017	13F
VANGUARD GROUP INC	13F	Company	1.4%	2,209,244	$46,726,000	—	31 Mar 2017	13F
JPMORGAN CHASE & CO	13F	Company	1.1%	1,630,487	$34,485,000	—	31 Mar 2017	13F
PFM Health Sciences, LP	13F	Company	0.97%	1,499,682	$31,718,000	—	31 Mar 2017	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.82%	1,268,479	$26,829,000	—	31 Mar 2017	13F
Carlson Capital, L.P.	13F	Company	0.78%	1,206,801	$25,524,000	—	31 Mar 2017	13F
STATE STREET CORP	13F	Company	0.72%	1,117,586	$23,638,000	—	31 Mar 2017	13F
ORBIMED ADVISORS LLC	13F	Company	0.7%	1,084,400	$22,935,000	—	31 Mar 2017	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.58%	900,317	$19,041,706	—	31 Mar 2017	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.52%	806,346	$17,054,000	—	31 Mar 2017	13F
JHL Capital Group LLC	13F	Company	0.45%	700,000	$14,805,000	—	31 Mar 2017	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.45%	696,149	$14,724,000	—	31 Mar 2017	13F
Rock Springs Capital Management LP	13F	Company	0.44%	675,000	$14,276,000	—	31 Mar 2017	13F
Cormorant Asset Management, LP	13F	Company	0.4%	620,300	$13,119,000	—	31 Mar 2017	13F
TIAA CREF INVESTMENT MANAGEMENT LLC	13F	Company	0.38%	586,875	$12,412,000	—	31 Mar 2017	13F
BROWN ADVISORY INC	13F	Company	0.29%	451,536	$9,550,000	—	31 Mar 2017	13F
Alyeska Investment Group, L.P.	13F	Company	0.29%	450,000	$9,518,000	—	31 Mar 2017	13F
PICTET ASSET MANAGEMENT LTD	13F	Company	0.29%	441,788	$9,344,000	—	31 Mar 2017	13F
PointState Capital LP	13F	Company	0.27%	421,300	$8,910,000	—	31 Mar 2017	13F
NORTHERN TRUST CORP	13F	Company	0.26%	407,934	$8,628,000	—	31 Mar 2017	13F
HIGHLAND CAPITAL MANAGEMENT LP	13F	Company	0.24%	378,230	$8,000,000	—	31 Mar 2017	13F
AXA S.A.	13F	Company	0.24%	368,752	$7,799,000	—	31 Mar 2017	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.21%	331,492	$7,011,000	—	31 Mar 2017	13F
BRIDGER MANAGEMENT, LLC	13F	Company	0.21%	329,345	$6,966,000	—	31 Mar 2017	13F
D. E. Shaw & Co., Inc.	13F	Company	0.21%	319,470	$6,757,000	—	31 Mar 2017	13F
S.c.a. Candriam	13F	Individual	0.19%	288,000	$6,091,000	—	31 Mar 2017	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.18%	272,749	$5,768,000	—	31 Mar 2017	13F
LORD, ABBETT & CO. LLC	13F	Company	0.15%	229,392	$4,852,000	—	31 Mar 2017	13F
COLUMBUS CIRCLE INVESTORS	13F	Company	0.14%	222,973	$4,716,000	—	31 Mar 2017	13F
TEACHERS ADVISORS, LLC	13F	Company	0.14%	219,671	$4,646,000	—	31 Mar 2017	13F
C WorldWide Group Holding A/S	13F	Company	0.12%	192,887	$4,080,000	—	31 Mar 2017	13F
Allianz Asset Management GmbH	13F	Company	0.12%	189,745	$3,975,000	—	31 Mar 2017	13F
Bellevue Group AG	13F	Company	0.11%	175,000	$3,701,000	—	31 Mar 2017	13F
Bank of New York Mellon Corp	13F	Company	0.11%	165,139	$3,492,000	—	31 Mar 2017	13F
CREDIT SUISSE AG/	13F	Company	0.11%	164,113	$3,472,000	—	31 Mar 2017	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	0.09%	145,000	$3,067,000	—	31 Mar 2017	13F
CITADEL ADVISORS LLC	13F	Company	0.09%	144,667	$3,060,000	—	31 Mar 2017	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.09%	141,095	$2,984,000	—	31 Mar 2017	13F
PRINCIPAL FINANCIAL GROUP INC	13F	Company	0.09%	138,440	$2,928,000	—	31 Mar 2017	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.09%	134,302	$2,841,000	—	31 Mar 2017	13F
Spark Investment Management LLC	13F	Company	0.08%	124,900	$2,641,000	—	31 Mar 2017	13F
KENNEDY CAPITAL MANAGEMENT LLC	13F	Company	0.08%	122,894	$2,599,000	—	31 Mar 2017	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.07%	113,200	$2,394,000	—	31 Mar 2017	13F
Rhenman & Partners Asset Management AB	13F	Company	0.07%	111,357	$2,355,000	—	31 Mar 2017	13F
VHCP Management II, LLC	13F	Company	0.06%	95,276	$2,015,000	—	31 Mar 2017	13F
SABBY MANAGEMENT, LLC	13F	Company	0.06%	93,308	$1,973,000	—	31 Mar 2017	13F
Tekla Capital Management LLC	13F	Company	0.06%	90,000	$1,904,000	—	31 Mar 2017	13F
DEUTSCHE BANK AG\	13F	Company	0.04%	67,811	$1,431,000	—	31 Mar 2017	13F

Institutional Holders of Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) as of Q2 2017

As of 30 Jun 2017, Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) was held by 105 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 40,123,971 shares. The largest 10 holders included FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, Kohlberg Kravis Roberts & Co. L.P., BlackRock Inc., VANGUARD GROUP INC, Partner Fund Management, L.P., STATE STREET CORP, JPMORGAN CHASE & CO, UBS ASSET MANAGEMENT AMERICAS INC, and ORBIMED ADVISORS LLC. This page lists 105 institutional shareholders reporting positions in this security for the Q2 2017 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2017 vs Q1 2017 Across Filers

Q1 2017 holders

109

Q2 2017 holders

105

Holder diff

-4

Investor	Q1 2017 Shares	Q2 2017 Shares	Share Diff	Share Chg %	Q1 2017 Value $	Q2 2017 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.